FRIDAY, June 22, 2018 (HealthDay News) — A novel handheld mHealth platform (Vivio) can accurately detect cardiac dysfunction in anthracycline-exposed childhood cancer survivors, according to a study published online June 21 in Clinical Cancer Research.
Saro H. Armenian, D.O., M.P.H., from the City of Hope in Duarte, Calif., and colleagues conducted a cross-sectional study to compare the accuracy of Vivio and echocardiography for assessment of cardiac function (left ventricular ejection fraction [EF]) in childhood cancer survivors with cardiac magnetic resonance (CMR) imaging. Concurrent evaluation of EF was performed using Vivio, two-dimensional echocardiography, and CMR. One hundred ninety-one consecutive survivors participated in the study. Their median anthracycline dose was 225 mg/m².
The researchers found that echocardiography overestimated mean EF by 4.9 percent; in linear regression analysis, a proportional bias was confirmed when compared with CMR. No difference was seen between mean EF derived from Vivio and CMR (−0.2 percent; P = 0.68). Compared with CMR, the detection of cardiac dysfunction via echocardiography was poor (Echo EF <45 percent: sensitivity, 14.3 percent; Echo EF <50 percent: sensitivity, 28.6 percent). Vivio-based measurements had considerably better sensitivity (EF <45 percent or EF <50 percent: sensitivity, 85.7 percent).
“This accessible technology has the potential to change the day-to-day practice of clinicians caring for the large number of patients diagnosed with cardiac dysfunction and heart failure each year, allowing real-time monitoring and management of their disease without the lag-time between imaging and interpretation of results,” the authors write.
Several authors disclosed financial ties, including ownership interests, to biotechnology companies.
Copyright © 2018 HealthDay. All rights reserved.